-+ 0.00%
-+ 0.00%
-+ 0.00%

HC Wainwright & Co. Maintains Buy on NovoCure, Raises Price Target to $47

Benzinga·02/12/2026 11:56:09
Listen to the news
HC Wainwright & Co. analyst Emily Bodnar maintains NovoCure (NASDAQ:NVCR) with a Buy and raises the price target from $39 to $47.